Multiple Sclerosis Abstracts

Abstracts 
41KB
A large number of abstracts covering all areas of Multiple Sclerosis. The most recent abstracts are still UN-sorted, but the older ones are hyper-linked.
Autonomic Dysfunction
11KB
The results of autonomic dysfunction tests show positive correlation to the MRI findings in patients with Multiple Sclerosis.
Axons
35 KB
Axons and disability in Multiple Sclerosis.
Bladder
13KB
Urological symptoms can appear even in the early stage of MS.
BBB
39KB
The cells, enzymes, and functions of the Blood-Brain Barrier.
Breathing
30KB
Respiratory dysfunction in Multiple Sclerosis.
CSF
11KB
CerebroSpinal Fluid analysis differentiates types of Multiple Sclerosis.
Childhood MS
10KB
Multiple Sclerosis in children.
Clinical Research
23KB
An overview of clinical trials and new therapeutic treatments for MS.
Cognition
12KB
PeriVentricular lesions in MS produce atrophy of the Corpus Callosum & Cognitive Impairment.
Complement
43KB
The Complement System.
Conduction 
18KB
Neuron transmissions in DeMyelinated Axons.
Cooling 
11KB
The benefits of *Cool* on MS Cognitive and Sensory abilities.
Copaxone 
28KB
Copaxone abstracts and WWW links.
Coronavirus 
17KB
Establishes molecular mimicry between a common Viral Pathogen and Myelin.
Cytokines
6KB
Cytokines regulate T-Cell activation by two pathways In MS.
Diagnosing MS
33KB
The diagnosis of Multiple Sclerosis.
Echinacea
24KB
How it safely modulates the Immune System.
Epidemiology
28KB
Studies on genetic and environmental factors commomly found in MS patients.
Fatigue
12KB
MS fatigue intensity and frequency are related and stem from Frontal Lobe DeMyelination.
Fampridine
40KB
Assessment of sustained-release 4-AminoPyridine (the generic form of Fampridine) for symptomatic treatment of Gait Spasticity in Multiple Sclerosis.
Gait
13KB
Gait abnormalities in Multiple Sclerosis.
Genetics
13KB
Genetic patterns involving HLA-DR & -DQ Class II Genes contribute to MS susceptibility and differing ethnic courses of disease.
Headache
23KB
A nonprescription combination of Acetaminophen, Aspirin, and Caffeine are highly effective for the treatment of migraine headaches.
Hearing
22KB
Positive correlatons of Auditory, Language and Speech dysfunctions in Multiple Sclerosis.
Helper T-Cells
35KB
The role of T-Helper cells and Cytokines in Multiple Sclerosis.
Histamine
20KB
Histamine and Procarin in Multiple Sclerosis.
Immune Cells
31KB
The CNS regulates Immune Responses. 
Interferon 
17KB
The rationale for early treatment of Multiple Sclerosis with Interferon: MSers produce less Type 1 IFNs: IFN-alpha & IFN-beta (IFN-ß). 
InterNuclear Ophthalmoplegia
27KB
InterNuclear Ophthalmoplegia (INO) is one of the NeuroOphthlamologic hallmarks of MS and is present in one third of MSers. 
IVIG
17KB
High-dose Intravenous Immune Globulin (IVIg) is important therapy for Neurologic diseases.
Mast Cells
26KB
Mast Cells in MS and inflammation.
Melatonin
11KB
Possible relationship between the seasonal variations of relapse and the age of onset in MS.
Mitochondria
34KB
Abstracts explaining how Mitochondria dysfunction or injury account for part of the NeuroDegeneration seen in the progression of MS.
Mitoxantrone
32KB
Promising results on the use of this therapy in treating Chronic/Progressive stages of MS.
Monoclonal 
29KB
Monoclonal studies and investigational therapies used to alter the course of MS.
MRI
45KB
Magnetic Resonance Imaging (MRI) in MS.
MS Mortality
26KB
Mortality statistics in Multiple Sclerosis.
Neurontin
16KB
Gabapentin (Neurontin) appears to ease the intractable pain of reflex sympathetic dystrophy.
Nitric Oxide
12KB
Nitric Oxide cause reversible conduction block in both normal and DeMyelinated Axons of the CNS.
Optic Neuritis
13KB
Studies to clarify the relationship between Optic Neuritis (ON) and Multiple Sclerosis.
Pain
17KB
InterLeukin-1, InterLeukin-6 and Tumor Necrosis Factor-alpha, are expressed by cells in the Spinal Cord as a result of nerve injury.
Pregnancy
18KB
Pregnancy does not increase disability in MS and ImmunoGlobulin treatments decrease the risk of postpartum exacerbations.
Prions
12KB
Prions recognized as agents that cause a number of infectious, Genetic and spontaneous disorders.
Proteolipid Protein
11KB
T-Cells recognize Myelin Proteolipid Protein (PLP) and PLP peptides, in MSers' peripheral Blood.
Prognosis
& Stages
 
17KB
Clinical factors of Multiple Sclerosis are analyzed for their validity in assessing its stages and long-term outcome.
PseudoBulbar Affect
26KB
The clinical features of PBA, a condition involving involuntary and uncontrollable episodes of crying and/or laughing.
ReMyelinate 
20KB
Continuing efforts to enhance and sustain Myelin growth.
Spasticity
23KB
Therapies for Multiple Sclerosis Spasticity.
Speech
22KB
Language disfunctions in Multiple Sclerosis.
Steroids
16KB
GlucoCorticoids (Steroids) in treating MS attacks.
Stress
14KB
Stress may contribute to immune changes associated with MS exacerbation.
Sweating
25KB
Sweating in Multiple Sclerosis
Temperature
23KB
Temperature and conduction block in MS.
Tremor
27KB
Tremor and movement disorders in MS.
Uric Acid
15KB
Uric acid administration was found to have a strong therapeutic effects in EAE.
Viruses
20KB
The implications of MicoOrganisms in MS.
Vitamin D
10KB
Vitamin D and the Immune System in Multiple Sclerosis.
Wallerian Degeneration
35KB
Diffuse Axonal disfunction and degeneration extends beyond MS lesions, along their projection pathways.





Medical Texts
Anatomy | Immune System | Lymphocytes | Meds
MHC | Movement | Cranial Nerves | Physiology


MS Glossary ThJuland's MSers' Glen - Our CyberHome Page Top The Glen's Gallery: Come & Share Our Stories MS Files MS Abstracts Site Index


Abstracts
ANS | Bladder | Cognition | Fatigue | Fluid | Genetics
Interferons | IVIG | Nitric Oxide | Optic Neuritis | Pain
Physiology | Prions | Prognosis | ReMyelinate | Steroids
Stress | Treatments | TNF | Uric Acid | Viruses



© Copyright 1997 - 2011:
Permission is granted to MS Societies and all MSers to utilize information from these pages provided that no financial reward is gained and attribution is given to the author/s.